- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00435227
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
July 22, 2021 updated by: MedImmune LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory tract of children who present with RSV illness but who do not require hospitalization.
Using 1:1 randomization, 30 mg/kg motavizumab or placebo will be administered as soon as possible after a child's diagnosis of RSV and his/her eligibility for the study has been confirmed.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg IM dose of motavizumab on viral load in the upper respiratory tract of children who present with RSV illness but who do not require hospitalization.
Participants were randomly assigned in a 1:1 ratio to 30 mg/kg motavizumab or placebo as soon as possible after a child's diagnosis of RSV and his/her eligibility for the study had been confirmed.
Randomization was stratified by age (<6 months and greater than or equal to 6 to less than or equal to 12 months of age) and by site.
Enrollment of an initial 100 children (50 per treatment group) will take place at multiple sites beginning in the 2006-2007 RSV season.
The study was terminated early due to inability to enroll the planned number of participants.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States
- Research Site
-
-
Arkansas
-
Jonesboro, Arkansas, United States
- Research Site
-
Jonesboro, Arkansas, United States, 72401
- Research Site
-
Little Rock, Arkansas, United States
- Research Site
-
Little Rock, Arkansas, United States, 72202
- Research Site
-
-
California
-
Orange, California, United States, 92868
- Research Site
-
San Diego, California, United States, 92103
- Research Site
-
-
Florida
-
Miami, Florida, United States
- Research Site
-
Tampa, Florida, United States, 33606
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Research Site
-
Augusta, Georgia, United States, 30912
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89107
- Research Site
-
-
New Jersey
-
Paterson, New Jersey, United States, 07503
- Research Site
-
-
New York
-
Bronx, New York, United States
- Research Site
-
Brooklyn, New York, United States, 11203-2098
- Research Site
-
Buffalo, New York, United States, 14222-2099
- Research Site
-
-
Ohio
-
Youngstown, Ohio, United States, 44051
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-2581
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75390
- Research Site
-
Dallas, Texas, United States, 75230
- Research Site
-
Houston, Texas, United States, 77030
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Research Site
-
-
West Virginia
-
Charleston, West Virginia, United States, 25302
- West Virginia University Pediactric Center
-
Charleston, West Virginia, United States, 72205
- Research Site
-
Huntington, West Virginia, United States, 25701-3655
- Research Site
-
Morgantown, West Virginia, United States, 26506
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Previously healthy
- Age ≤12 months at the time of randomization
- Weight ≤10 kg at the time of randomization
- Gestational age ≥36 weeks
- RSV illness (must have coryza) documented by a positive RSV test at the time of evaluation
- Documented stable clinical condition that does not require hospitalization (oxygen saturation ≥ 95%; respiratory rate < 60 breaths/minute in children < 2 months and < 50 breaths/minute in children 2-12 months)
- Respiratory Distress Assessment Instrument (RDAI) score of ≤ 6 (there can be no more than 1 point assigned for each of the 6 assessment categories) at baseline evaluation
- Randomization within 4 hours of being evaluated with a positive Binax® RSV test
- Written informed consent obtained from the participant's parent(s) or legal guardian
Exclusion Criteria:
- Prior receipt of or receiving treatment with steroids (except topical steroids) prior to randomization
- Prior medically diagnosed RSV infection
- Prior receipt of or receiving anti-viral treatment for the current episode of RSV infection prior to randomization
- Any medically significant underlying ongoing chronic illness or organ system dysfunction or other known acute illness, other than the acute RSV infection
- Known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or other neurologic disorder or immunodeficiency
- Requirement for supplemental oxygen (brief use of oxygen in the immediate postnatal period to treat a transient condition is allowed)
- Mechanical ventilation at any time prior to the onset of the current RSV infection
- Congenital heart disease [children with medically or surgically closed patent ductus arteriosus (PDA), small atrial septal defect (ASD) or small ventricular septal defect (VSD) will be allowed]
- Previous reaction to intravenous immunoglobulin (IVIG), blood products, or other foreign proteins
- Prior use of IVIG, RSV-IGIV (RespiGam®), motavizumab or other immunoglobulin products within the past 2 months
- Prior use of palivizumab (Synagis®) within the past 2 months
- Currently receiving other investigational agents or have received any other investigational agents within the last 3 months
- Prior or current participation in any investigational study with a therapeutic agent or vaccine for RSV
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motavizumab
Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
|
A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
Other Names:
|
Placebo Comparator: Placebo
Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
|
A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory Syncytial Virus (RSV) Load in the Upper Respiratory Tract of RSV-infected Participants as Measured by Reverse Transcriptase-polymerase Chain Reaction (RT-PCR) at Day 0
Time Frame: Day 0
|
The RSV viral load is measured by real-time RT-PCR in the RSV-infected participants.
RSV-infected children are those who are positive for any RSV by RT-PCR of nasal wash aspirates.
|
Day 0
|
RSV Load in the Upper Respiratory Tract of RSV-infected Participants as Measured by RT-PCR at Day 2
Time Frame: Day 2
|
The RSV viral load is measured by real-time RT-PCR in the RSV-infected participants.
RSV-infected children are those who are positive for any RSV by RT-PCR of nasal wash aspirates.
|
Day 2
|
RSV Load in the Upper Respiratory Tract of RSV-infected Participants as Measured by RT-PCR at Day 30
Time Frame: Day 30
|
The RSV viral load is measured by real-time RT-PCR in the RSV-infected participants.
RSV-infected children are those who are positive for any RSV by RT-PCR of nasal wash aspirates.
|
Day 30
|
RSV Load in the Upper Respiratory Tract of RSV-infected Participants as Measured by RT-PCR at Day 90
Time Frame: Day 90
|
The RSV viral load is measured by real-time RT-PCR in the RSV-infected participants.
RSV-infected children are those who are positive for any RSV by RT-PCR of nasal wash aspirates.
|
Day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Have Progression of RSV Illness That Requires Subsequent Hospitalization
Time Frame: From Randomiation (Day 0) Up to Day 30
|
The percentage of participants who have progression of RSV illness that requires subsequent hospitalization is reported.
RSV illness symptomps included fever, coryza, cough, and parental opinion of return to normal health and activity.
|
From Randomiation (Day 0) Up to Day 30
|
Respiratory Assessment Change Score (RACS) Derived From Baseline
Time Frame: Baseline (Day 0); and Days 2, 7, and 30
|
The RACS assesses changes in wheezing and retractions as measured by the respiratory distress assessment instrument (RDAI) score and changes in respiratory rate.
A RDAI score is a measure of the degree of severity of wheezing and retractions, with score range from 0 to 17; higher scores indicate more severe disease.
Respiratory rate is summarized by raw scores and standardized change score.
Change in respiratory rate of less than or equal to (<=) 5% from baseline is counted as a change of 0 units and a change in respiratory rate is assigned 1 point per each 10% change in respiratory rate.
The RACS is calculated as arithmetic sum of RDAI score change and of the standardized respiratory rate change (for example, a child showing improvement who had a RDAI of -5 and a respiratory rate change of -2 would have a RACS score of -7).
The RACS assessment does not have a minimum and/or maximum scale range.
A decrease in RACS represents improvement, whereas an increase signifies deterioration.
|
Baseline (Day 0); and Days 2, 7, and 30
|
Change From Baseline in Oxygen Saturation Level
Time Frame: Baseline (Day 0), Days 2, 7, and 30
|
Change from baseline in oxygen saturation level is reported.
|
Baseline (Day 0), Days 2, 7, and 30
|
Change in RACS of RSV-infected Outpatient Participants Who Subsequently Required Hospitalization
Time Frame: Baseline (Day 0) to Day 30
|
The RACS assesses changes in wheezing and retractions as measured by the RDAI score and changes in respiratory rate.
A RDAI score is a measure of the degree of severity of wheezing and retractions, with score range from 0 to 17; higher scores indicate more severe disease.
Respiratory rate is summarized by raw scores and standardized change score.
A change in respiratory rate of <= 5% from baseline is counted as a change of 0 units and a change in respiratory rate is assigned 1 point per each 10% change in the respiratory rate.
The RACS is calculated as the arithmetic sum of the RDAI score change and of the standardized respiratory rate change (for example, a child showing improvement who had a RDAI of -5 and a respiratory rate change of -2 would have a RACS score of -7).
The RACS assessment does not have a minimum and/or maximum scale range.
A decrease in the RACS represents improvement, whereas an increase signifies deterioration.
|
Baseline (Day 0) to Day 30
|
Oxygen Saturation Levels in RSV-infected Outpatient Participants Who Subsequently Required Hospitalization
Time Frame: Baseline (Day 0) to Day 30
|
Baseline (Day 0) to Day 30
|
|
Heart Rate of RSV-infected Outpatient Participants Who Subsequently Required Hospitalization
Time Frame: Baseline (Day 0) to Day 30
|
Baseline (Day 0) to Day 30
|
|
Respiratory Rate of RSV-infected Outpatient Participants Who Subsequently Required Hospitalization
Time Frame: Baseline (Day 0) to Day 30
|
Baseline (Day 0) to Day 30
|
|
Number of Participants Who Required Hospitalization, Intensive Care Unit (ICU) Stay, Supplemental Oxygen, and Mechanical Ventilation
Time Frame: Baseline (Day 0) to Day 90
|
Number of participants who required hospitalization, ICU stay, supplemental oxygen, and mechanical ventilation is reported.
|
Baseline (Day 0) to Day 90
|
Duration of Hospitalization, ICU Stay, Supplemental Oxygen Used, and Mechanical Ventilation Required
Time Frame: Baseline (Day 0) to Day 90
|
Baseline (Day 0) to Day 90
|
|
Number of Participants Who Progresses From Upper Respiratory Tract Infection to Lower Respiratory Tract Infection (LRI)
Time Frame: Baseline (Day 0) to Day 30
|
A LRI event is one that has a medical diagnosis of bronchiolitis or pneumonia.
In the absence of such a medical diagnosis, the occurrence of LRI events will be determined by the principal investigator after review of the medical record and based on the presence of retractions or lower respiratory tract rhonchi, wheezing, crackles, or rales in children with a positive RSV test.
|
Baseline (Day 0) to Day 30
|
Number of LRI Infected Participants Who Required Hospitalization, ICU Stay, Supplemental Oxygen, Mechanical Ventilation, and Respiratory Medications
Time Frame: Baseline (Day 0) to Day 30
|
Number of LRI infected participants who required hospitalization, ICU stay, supplemental oxygen, mechanical ventilation, and respiratory medications are reported.
|
Baseline (Day 0) to Day 30
|
RACS in Participants With LRI
Time Frame: From Baseline (Day 0) to Days 2, 7, and 30
|
The RACS assesses changes in wheezing and retractions as measured by RDAI score and changes in respiratory rate.
A RDAI score is a measure of degree of severity of wheezing and retractions, with score range from 0 to 17; higher scores indicate more severe disease.
Respiratory rate is summarized by raw scores and standardized change score.
A change in respiratory rate of <= 5% from baseline is counted as a change of 0 units and a change in respiratory rate is assigned 1 point per each 10% change in the respiratory rate.
The RACS is calculated as the arithmetic sum of the RDAI score change and of the standardized respiratory rate change (for example, a child showing improvement who had a RDAI of -5 and a respiratory rate change of -2 would have a RACS score of -7).
The RACS assessment does not have a minimum and/or maximum scale range.
A decrease in the RACS represents improvement, whereas an increase signifies deterioration.
RACS in participants with LRI is reported.
|
From Baseline (Day 0) to Days 2, 7, and 30
|
Motavizumab Concentration in Upper Respiratory Tract
Time Frame: Days 0 (pre-dose), 2, and 30
|
Motavizumab concentration in upper respiratory tract (nasal wash aspirates) is reported.
|
Days 0 (pre-dose), 2, and 30
|
Serum Concentration of Motavizumab
Time Frame: Days 2, 30, and 90
|
Serum concentration of motavizumab is reported.
|
Days 2, 30, and 90
|
Numbers of Participants With Positive Anti-Motavizumab Antibodies
Time Frame: Days 0 (pre-dose) and 90
|
The number of participants with positive serum antibodies to motavizumab are reported.
|
Days 0 (pre-dose) and 90
|
Serum Cytokine Levels
Time Frame: Days 0 (pre-dose), 30, and 90
|
Serum Cytokine Levels are reported.
|
Days 0 (pre-dose), 30, and 90
|
Nasal Wash Cytokine Levels
Time Frame: Days 0 (pre-dose), 2, 30, and 90
|
Nasal wash cytokine levels are reported.
|
Days 0 (pre-dose), 2, 30, and 90
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: From the administration of study drug (Day 0) through Day 90
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
|
From the administration of study drug (Day 0) through Day 90
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: M. Pamela Griffin, M.D., MedImmune LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2007
Primary Completion (Actual)
May 31, 2008
Study Completion (Actual)
May 31, 2008
Study Registration Dates
First Submitted
February 13, 2007
First Submitted That Met QC Criteria
February 13, 2007
First Posted (Estimate)
February 14, 2007
Study Record Updates
Last Update Posted (Actual)
August 17, 2021
Last Update Submitted That Met QC Criteria
July 22, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MI-CP146
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Participants Less Than 12 Months of Age With RSV Illness
-
MedImmune LLCCompletedRSV Illness in ≤12 Months of ParticipantsUnited States, Chile, New Zealand, Australia, Panama
-
Novartis PharmaceuticalsWithdrawnPatients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
-
University of Colorado, DenverChildren's Hospital Colorado; Mead Johnson NutritionRecruitingHealthy Toddlers 12-36 Months of Age With Mild or Moderate MalnutritionUnited States
-
University Hospital, Strasbourg, FranceTerminatedFor Oncologic Patients | Potentially Operable Lung Tumor | With a Recent (Less Than 1 Month) VQ Scan | For Lung Transplant Recipients | Single of Bilateral Lung Transplant | From 5 Months Onwards | With Recent (Less Than 1 Month) Respiratory Functional ExplorationsFrance
-
Hospices Civils de LyonNot yet recruitingRhinovirus | RSV Infection in Children Less Than 5 Years of AgeFrance
Clinical Trials on Motavizumab
-
MedImmune LLCCompletedRespiratory Syncytial Virus Infections | Chronic Lung Disease and <= 24 Months of Age or | Premature With Gestational Age <=35 Weeks and <=6 Months of AgeAustralia, Chile, New Zealand
-
MedImmune LLCWithdrawn
-
MedImmune LLCCompleted
-
MedImmune LLCCompletedMotavizumab Administration for a Second Season for RSV ProphylaxisChile, Brazil
-
MedImmune LLCCompletedRespiratory Syncytial Virus Prophylaxis
-
MedImmune LLCCompleted
-
MedImmune LLCCompletedRSV Illness in ≤12 Months of ParticipantsUnited States, Chile, New Zealand, Australia, Panama
-
MedImmune LLCCompletedCongenital Heart DiseaseUnited States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
-
MedImmune LLCCompletedRespiratory Syncytial Virus InfectionsUnited States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...